

Reference Number: FOI202223/265
From: Private Individual
Date: 26 August 2022
Subject: Treatment for Lung Cancer with various drugs

- Q1 In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:
- a. Afatinib
 - b. Alectinib
 - c. Atezolizumab monotherapy
 - d. Atezolizumab in combination
 - e. Bevacizumab
 - f. Brigatinib
 - g. Capmatenib
 - h. Ceritinib
 - i. Crizotinib
 - j. Dacomitinib
 - k. Dabrafenib with Trametinib
 - l. Docetaxel monotherapy
 - m. Durvalumab
 - n. Erlotinib
 - o. Gefitinib
 - p. Gemcitabine
 - q. Nintedanib with Docetaxel
 - r. Nivolumab
 - s. Osimertinib
 - t. Paclitaxel
 - u. Pembrolizumab monotherapy
 - v. Pembrolizumab in combination
 - w. Pemetrexed with Carboplatin/Cisplatin
 - x. Tepotinib
 - y. Vinorelbine with Cisplatin/Carboplatin
 - z. Any other SACT
 - aa. Palliative care only

A1 a - aa: None